Intratumoral mRNA levels predict clinical outcome in patients with metastatic colorectal cancer treated in a prospective clinical trial with 5-FU and oxaliplatin.

被引：0
|
作者：
Yang, D.
Vallböhmer, D.
Zhang, W.
Iqbal, S.
El-Khoueiry, A.
Gordon, M.
Park, D.
Azuma, M.
Groshen, S.
Danenberg, K. D.
Lenz, H.
机构：
[1] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90089 USA
[2] Response Genet Inc, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10010
引用
收藏
页码：543S / 543S
页数：1
相关论文
共 50 条
  • [1] Molecular profiling predicts clinical outcome in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin.
    Yun, J
    Zhang, W
    Park, D
    Yang, D
    Press, O
    Gordon, M
    Mallik, N
    Lenz, HJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 249S - 249S
  • [2] AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
    J B Kjersem
    M Thomsen
    T Guren
    J Hamfjord
    G Carlsson
    B Gustavsson
    T Ikdahl
    G Indrebø
    P Pfeiffer
    O Lingjærde
    K M Tveit
    Y Wettergren
    E H Kure
    [J]. The Pharmacogenomics Journal, 2016, 16 : 272 - 279
  • [3] AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
    Kjersem, J. B.
    Thomsen, M.
    Guren, T.
    Hamfjord, J.
    Carlsson, G.
    Gustavsson, B.
    Ikdahl, T.
    Indrebo, G.
    Pfeiffer, P.
    Lingjaerde, O.
    Tveit, K. M.
    Wettergren, Y.
    Kure, E. H.
    [J]. PHARMACOGENOMICS JOURNAL, 2016, 16 (03): : 272 - 279
  • [4] Effect of celecoxib on neurotoxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin (CIFOX).
    Agafitei, RD
    Schneider, S
    Iqbal, S
    Yang, D
    Groshen, S
    Lenz, HJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 270S - 270S
  • [5] Pilot trial of 5-FU/oxaliplatin (CIFOX) for patients with metastatic colorectal cancer who progressed on 5-FU/LV/CPT-11 (IFL).
    Aparicio, A
    Iqbal, S
    Yang, D
    Groshen, S
    Park, D
    Garcia, A
    Lenz, HJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 312S - 312S
  • [6] Oxaliplatin with 5-FU or as a single agent in advanced/metastatic colorectal cancer
    Mitchell, EP
    [J]. ONCOLOGY-NEW YORK, 2000, 14 (12): : 30 - 32
  • [7] Independent clinical validation of a gene expression profile to predict benefit of 5-FU in metastatic colorectal cancer
    Buhl, I. K.
    Carlsson, G. U.
    Saksena, P.
    Gustavsson, B.
    Christensen, I. J.
    Edsjo, A.
    Hansen, A.
    Knudsen, S.
    Jensen, P. B.
    Wettergren, Y.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [8] Polymorphisms in angiogenesis related genes predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV)
    Shaye, O. S.
    Chang, H. M.
    Yang, D. Y.
    Shriki, J.
    Schultheis, A. M.
    Zhang, W.
    Lurje, G.
    Iqbal, S.
    Lenz, H. J.
    El-Khoueiry, A. B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Use of genetic variants to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV)
    Singh, H.
    Pohl, A.
    El-Khoueiry, A.
    Lurje, G.
    Zhang, W.
    Yang, D.
    Ning, Y.
    Shriki, J.
    Iqbal, S.
    Lenz, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Intratumoral induction of thymidylate synthase mRNA by 5-FU in colorectal cancer patients:: association with survival
    Tanaka-Nozaki, M
    Tajiri, T
    Tanaka, N
    Furukawa, K
    Takasaki, H
    Yoshimura, K
    Suzuki, H
    Naito, Z
    Sugizaki, Y
    Merk, HF
    Blömeke, B
    Kato, S
    [J]. ONCOLOGY REPORTS, 2003, 10 (05) : 1425 - 1429
12345